MedTrace Logo

Identification of Potential Biomarkers of Response to Peptide Immunotherapy for Ragweed Allergy

NCT01361412 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2011-10-07

No results posted yet for this study

Summary

The aim of the study is to identify changes in potential biomarkers after peptide immunotherapy for that may subsequently be developed as biomarkers that correlate with clinical efficacy.

Conditions

  • Ragweed Allergy

Interventions

BIOLOGICAL

ToleroMune Ragweed

Intradermal administration 1x8 administrations, 2 weeks apart

BIOLOGICAL

Placebo

Intradermal injection 1x8 administrations, 2 weeks apart

Sponsors & Collaborators

  • Adiga Life Sciences, Inc.

    collaborator INDUSTRY

  • Cetero Research, San Antonio

    collaborator NETWORK

  • Circassia Limited

    lead INDUSTRY

Principal Investigators

  • Deepen Patel, MD, CCFP · Cetero Research, San Antonio

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01361412 on ClinicalTrials.gov